HCM Q4 2023 Earnings — HUTCHMED (China) Limited Revenue & Financial Results | Market Cap Arena

HCMHUTCHMED (China) Limited

$3B

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$153M+36.0% YoY

Gross Profit

-$14M-9.3% margin

Operating Income

-$47M-30.6% margin

Net Income

-$34M-22.2% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$8M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$536M

Stockholders' Equity

$731M

Cash & Equivalents

$284M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$153M	$112M	+36.0%
Gross Profit	-$14M	-$77M	+81.6%
Operating Income	-$47M	-$105M	+55.8%
Net Income	-$34M	-$99M	+65.8%

Revenue Segments

Collaboration Research And Development

$52M43%

Other Collaboration Licensing Revenue

$29M24%

Commercialization Services

$23M19%

Other Collaboration Royalties Revenue

$17M14%

Research And Development Services

$235,0000%